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Abstract
Purpose: Osteoradionecrosis (ORN) of the mandible is a serious complication of head 
and neck radiotherapy. This study aims to investigate the effect of hyperbaric oxygen 
(HBO) treatment on ORN in two randomized, controlled multicentre trials.
Methods and materials: Patients with ORN with indication for surgical treatment were 
randomised to either group 1: surgical removal of necrotic mandibular bone 
supplemented by 30 pre- and 10 postoperative HBO exposures at 243 kPa for 90 
minutes each, or group 2: surgical removal of necrotic bone only. Primary outcome was 
healing of ORN one year after surgery evaluated by a clinically adjusted version of the 
Common Toxicity Criteria of Adverse Events (CTCAE) v 3.0. Secondary outcomes 
included xerostomia, unstimulated and stimulated whole salivation rates, trismus, 
dysphagia, pain, Activities of Daily Living (ADL) and quality of life according to EORTC. 
Data were combined from two separate trials. Ninety-seven were enrolled and 65 were 
eligible for the intent-to-treat analysis. The 33% drop-out was equally distributed 
between groups.
Results: In group 1, 70% (21/30) healed compared to 51% (18/35) in group 2. HBO was 
associated with an increased chance of healing independent of baseline ORN grade or 
smoking status as well as improved xerostomia, unstimulated whole salivary flow rate, 
and dysphagia. Due to insufficient recruitment, none of the endpoints reached a 
statistically significant difference between groups. ADL data could only be obtained from 
50 patients.
Conclusion: Hyperbaric oxygen did not significantly improve the healing outcome of 
osteoradionecrosis after surgical removal of necrotic bone as compared to standard 
care (70% vs. 51%). This effect is not statistically significant due to the fact that the 
study was underpowered and is therefore prone to type II error. 
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Introduction
Worldwide, approximately 710,000 patients are diagnosed annually with head and neck 
cancer (HNC) [1,2]. 
Radiotherapy (RT) plays a major role in the treatment of HNC, either alone or in 
combination with chemotherapy and/or surgery. Osteoradionecrosis (ORN) is a serious 
complication of head and neck RT. It is defined as exposed bone after RT that fails to 
heal over a period of three months without evidence of persistent or recurrent cancer 
[3,4]. Recently, published data have indicated that the incidence is less than 5-6% of 
HNC patients treated with RT [5,6]. However, ORN remains a serious problem. Speech, 
eating, oral hygiene and dental rehabilitation are challenging, especially  combined with 
xerostomia, dysphagia and trismus [7–9]. Hence, quality of life is often severely affected 
in ORN patients [10]. 
Hyperbaric oxygen (HBO) therapy is used adjunctively to surgical removal of ORN [11]. 
HBO stimulates angiogenesis, increases neovascularization, fibroblast and osteoblast 
proliferation, and collagen formation in irradiated tissues [12,13]. It is assumed to 
improve the conditions of the tissues that are marked by decreased vascularization, 
diminished oxygen supply, and decreased ability to recover after a minor trauma, such 
as tooth extraction. 
However, the benefit of HBO in mandibular ORN remains controversial because of low 
evidence. Only one randomised clinical trial (RCT) has been conducted, while several 
cohort studies of variable quality have been published, reporting ORN recovery rates 
from zero to 100 percent [14–23][24–29] The studies are hardly comparable due to 
variation in the application of HBO, as well as variability of the study designs, 
classification, and severity of ORN. Consequently, there has been a need for further 
investigation of the clinical effect of HBO on ORN. For this purpose, the DAHANCA-21 
trial and the NWHHT2009-1 trial were initiated in a multicentre collaboration involving 
Danish, Dutch, British and Swedish Centres. The main primary and secondary 
endpoints of the trials were adjusted in a very early stage before accrual, to make it 
possible to merge the trials if the accrual rate would become a problem for both trials. 
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Patients and methods 
Protocol design and patient eligibility
The study was a multicentre trial consisting of pooled data from two separate 
randomised trials with the same main primary endpoint. The secondary endpoints were 
partially adjusted. Data were pooled because of recruitment difficulties. DAHANCA-21 
was conducted in Denmark (one site), Sweden (one site) and the United Kingdom (five 
sites), and NWHHT2009-1 in the Netherlands (five sites).
The DAHANCA-21 trial was granted ethics approval by the Regional Ethics Committee 
of the Capital Region of Denmark (H-A-2008-031). Approval was obtained from The 
Danish Medicines Health Agency (EudraCT no. 2007-007842-36). The NWHHT2009-1 
trial was granted ethics approval by the Dutch Central Committee on Research 
Involving Human Subjects (CCMO NL20963.091.08 EudraCT no. 2008-001972-55). 
Both studies were conducted in accordance with Good Clinical Practice (DAHANCA-21 
NCT 00760682 and NWHTT2009-1 NCT 00989820).
Eligible participants were aged ≥18 years with osteoradionecrosis of the mandible 
requiring surgical removal of necrotic bone after RT for head and neck cancer (any site). 
Patients were considered non-eligible if they were previously treated with HBO, had 
active cancer or contraindications to HBO such as a pneumothorax, uncontrolled 
hypertension, uncontrolled epilepsy, or claustrophobia that could not be treated with 
medication. Participants were randomly assigned (1:1) to receive or not to receive HBO 
supplemental to surgical removal of necrotic mandibular bone. Allocation of treatment 
was unblinded to patients and investigators. 
In DAHANCA-21, participants were stratified according to ORN grade and centre. 
Patients in NWHHT2009-1 were not stratified. 
Ninety-seven patients were enrolled and 65 were included in the statistical analysis. The 
dropout rate was 33%. Of the 32 patients who dropped out, the distribution was 16 in 
each group. Reasons for drop out is shown in Figure 1. 
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Demographic data and follow-up.
Baseline demographic patient data included treatment centre, sex, age, smoking, BMI, 
pain, dental status, and baseline ORN. The surgical procedure and number of HBO 
treatments were recorded.
Patient reported outcome measures (PROMs) included xerostomia, dysphagia, ability to 
take liquids, trismus, and quality of life measures according to EORTC QLQ-C30 and 
Activities of Daily Living measures (ADL). 
Patients were followed for one year after planned surgery for evaluation of the primary 
endpoints. Secondary endpoints were evaluated at 3 months after planned surgery.
Surgical treatment
Surgery was performed according to the extent of the bone necrosis, as judged by the 
treating clinician. Small necrotic lesions were treated by removal of small sequesters, 
while larger necrotic lesions were treated with larger resections with or without 
discontinuation of the mandible. Some patients with discontinuation of the mandible 
were reconstructed with a free vascularised bone graft.
HBO treatment
For the patients in the HBO arm, 100% oxygen was individually delivered through a 
hood or tight-fitting mask in a pressurised room at 243 kPa (2.4 atmospheres absolute) 
for 90 minutes in 40 daily sessions five days a week (30 pre- and 10 postoperative). The 




The primary endpoint was healing of ORN after one year as evaluated by an adjusted 
version of the Common Toxicity Criteria of Adverse Events (CTCAE) v 3.0 [31], as 
shown in Table 1.
Secondary endpoints
Secondary endpoints measured in both trials were Quality of Life (EORTC QLQ-C30 
and QLQ-H&N35), pain assessment (VAS scale and analgesics consumption) and 
smoking habits. 
Other secondary endpoints that were measured by the DAHANCA-21 trial only were 
unstimulated and stimulated salivation rate (ml/min), xerostomia (UKU side effect rating 
scale [32]). Unstimulated whole saliva (UWS) was collected by the draining method in a 
pre-weighed cup for a period of 15 minutes. Stimulated whole saliva was collected for a 
period of 5 minutes while chewing a piece of paraffin wax (1 g). Salivary flow rates were 
estimated by dividing the saliva volume (1 g of saliva equals 1 mL) by the collection time 
[33]. 
In DAHANCA-21, five questions were used to assess ADL. These included denture 
wear, tooth brushing, eating, eating with others and being with others, as evaluated by 
use of an ordinal scale from 0 to 4 (0=no problems, 1=slightly problematic, but do not 
need to refrain from, 2=sometimes problematic, must seldom refrain from, 
3=problematic, must often refrain from, and 4=not possible to do). The registered ADL 
score for each participant was the highest score achieved among all five questions. 
Changes in ADL at 1 year were calculated as the number of points lower than at 
baseline, i.e. positive numbers indicate improvement. ADL improvement was 
dichotomized as ‘No change or improvement’ (change ≥0) versus ‘Worsening’ (change 
<0).
Xerostomia and dysphagia were assessed using an ordinal scale from 0 to 4 according 
to DAHANCA. Additional secondary endpoints in the DAHANCA21 trial were trismus 
(interincisal distance, or in edentulous patients, the distance between the alveolar 
ridges), and dysphagia (CTCAE v 3.0). 
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A secondary endpoint that was only measured in the NWHHT2009-1 trial was the 
amount of additional surgical interventions needed to treat the ORN lesion.
Statistics 
Both trials were activated in 2008 and planned to include a total of 114 patients 
(DAHANCA-21) and 120 patients (NWHHT2009-1), respectively, and the trials were 
powered to detect a difference of 25% between the two treatment groups.
Differences in patient and treatment characteristics were evaluated by Fisher's exact 
test (ordinal data) and t-test or Wilcoxon rank-sum test (continuous data). Frequency 
distributions and Q-Q-plots were used for checking normality visually. 
Differences in frequencies (1 year after surgery) of patients healed were evaluated by 
Chi-squared test and expressed as odds ratio.
Factors affecting ORN healing 1 year after surgery were evaluated in an exploratory 
univariate logistic regression analysis of protocol, baseline ORN grades, treatment type, 
smoking, sex, and age. Collinearity was assessed by the variance inflation factor (VIF). 
All variables had VIFs <1.6, however, baseline ORN grades and treatment types were 
correlated, with higher baseline grades being associated with more intensive treatment 
(p<0.001, Chi-squared test). 
The final multivariate model included baseline ORN values and smoking (never versus 
former/current). Compared to a model with treatment type instead of baseline ORN 
values, the AIC (Akaike Information Criterion) was 88 for the model with baseline values 
and 85 for the model with treatment type, and the coefficients for protocol were similar 
(test for equality, p=0.81). 
Probabilities of healing in non-smokers versus former/current smokers was calculated 
as AAPs (Average Adjusted Predictions) and AMEs (Average Marginal Effects). Factors 
affecting ORN grade 1 year after surgery were evaluated likewise using an exploratory 
univariate logistic regression analysis and a final multivariate model including baseline 
ORN values and smoking (never versus former/current). 
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The effect of HBO on changes in ADL grade were evaluated by Wilcoxon rank-sum test 
for changes from baseline to 1 year after surgery and by Fisher's exact test for binary 
groups.
Secondary endpoints were evaluated using mixed-effect models with time of visit 
(baseline, 3 months follow-up, 1-year follow-up), treatment arm, interaction between 
visit and treatment arm, and smoking (never versus former/current) as fixed effects and 
patient as random effect. BMI, dysphagia (EORTC H&N35), pain (VAS), and global 
health status (EORTC QLQ-C30) were evaluated by linear mixed-effects regression 
models using an unstructured covariance matrix. The remaining secondary endpoints 
were evaluated by mixed effects binary logistic regression models. Predicted scores 
and differences between treatment arms were calculated as AAPs and AMEs.
The analyses were performed using Stata 16.1 (StataCorp, Texas, USA).
Results
Patient and treatment characteristics
Table 2 shows patient and treatment characteristics. No differences were observed for 
age, sex, smoking status, type of surgery, or ADL between patients treated with surgery 
or surgery + HBO. Of the 30 patients in the HBO arm, 26 (87%) received 40 treatments 
(Figure 1).
Effect of HBO on ORN healing
The primary clinical endpoint was healing of ORN 1 year after surgery. First, healing 
was defined as a binary outcome with healed (grade 0-1) versus not healed (grade 2-4). 
One year after surgery, healing was observed in 18 out of 35 patients (51%) treated 
with surgery alone and in 21/30 patients (70%) treated with surgery + HBO (p=0.13) 
with an odds ratio for being healed of 2.2 (95% CI: 0.7-7.0) (Table 3). Second, the effect 
of protocol, baseline ORN grades, treatment type, smoking, sex, and age were tested in 
an exploratory univariate binary logistic regression analysis using ORN healing as 
endpoint (Supplementary Table 1). With only 65 patients included, and with missing 
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values for some of the factors, caution must be taken when interpreting the results in a 
multivariate analysis. With these reservations, a final model was constructed with 
baseline ORN grades (grade 2 vs grade 3 or 4) and smoking (never versus former or 
current) as covariates, resulting in an adjusted odds ratio of 2.7 (0.9-8.0, p=0.083) for 
healing when using HBO (Supplementary Table 2). Tests for interaction for protocol and 
baseline grade (p=0.99) and protocol and smoking (p=0.88) indicate that HBO is 
associated with an increased chance of healing independent of baseline ORN grade or 
smoking status. 
Predictions for frequency of patients healed are shown in Figure 2. The predicted 
percentage of being healed 1 year after surgery increases when HBO is used with 14% 
(-3-31) for baseline grade 2, 22% (-2-46) for baseline grade 3/4, 14% (-4-33) for never 
smokers, and 23% (-2-47) for former/current smokers.
Similar results were obtained using ORN grades on an ordinal scale. Supplementary 
Table 3 shows the results of a univariate ordinal logistic regression analysis, and 
Supplementary Table 4 shows the results of the final model, resulting in an adjusted 
odds ratio of 1.8 (p=0.23) for having a lower grade after 1 year when using HBO. Tests 
for interaction were performed for protocol and baseline grade (p=0.58) and protocol 
and smoking (p=0.83). 
Effect of HBO on change in activities of daily living
The primary PROM was change in ADL from baseline to 1 year after surgery. ADL data 
were available from 53 of the 65 patients, and the distribution of ADL scores at baseline 
was similar in the two treatment arms (Table 3). The changes in ADL score are 
illustrated in Figure 3, where zero indicates no change and positive values indicate 
improvement in ADL score (the score is reduced). Overall, the changes in ADL score 
were not significantly different (p=0.29). If changes in ADL score were reduced to a 
binary outcome, no change or improvement vs. worsening, there were 17 patients 
(59%) experiencing no change or improvement with surgery alone vs. 19 (79%) with 
surgery + HBO (p=0.15). 
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Secondary endpoints
Secondary endpoints were evaluated using mixed-effect models. Predicted outcomes at 
baseline, 3 months follow-up, and 1-year follow-up are shown in Supplementary Figure 
1. Differences between treatment arms at each time point are listed in Supplementary 
Table 5.
Several endpoints appeared to show beneficial effects over time for surgery + HBO 
compared to surgery alone. The surgery + HBO arm appeared to be more beneficial for 
xerostomia (DAHANCA), unstimulated whole saliva flow rates, and dysphagia 
(DAHANCA).
Nevertheless, none of the endpoints showed a significant difference due to the fact that 
the study was underpowered. 
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Discussion
DAHANCA-21 and NWHHT2009-1 are the first randomised, controlled trials of HBO + 
surgery treatment for ORN in head and neck patients investigating a standard HBO 
protocol with 30 preoperative and 10 postoperative exposures delivered daily during a 
period of respectively 6 and 2 weeks. 
Seventy percent of participants in the present study showed successful recovery when 
HBO was administered as a supplement to surgical removal of necrotic bone. 
Correspondingly, this was the case for 51% of the participants who received surgical 
treatment only. Apparently, an increased chance of healing was observed after surgery 
+ HBO independent of baseline ORN grade or smoking status. Multivariate regression 
analysis did not show a statistically significant difference between the two groups. 
Explanatory, the power calculation performed prior to trial initiation aimed at detecting a 
difference of 25%. Furthermore, the number of 114 cases for achieving adequate power 
was not obtained due to a low patient accrual rate in both trials. This is an obvious 
shortcoming which must be considered when interpreting the results of the analysis. 
Although low patient accrual was expected, it was surprisingly low in both DAHANCA-
21 and NWHHT2009-1. One possible explanation for this is the decreasing incidence of 
ORN due to improved RT techniques [5,34]. Additionally, a major reason was that the 
majority of patients who refused participation, did so because HBO was also offered 
without any requirement for trial participation. Others refused because they lacked 
mental or physical energy to complete 40 HBO treatments due to comorbidities or for 
other personal reasons. Some patients were not offered participation because it could 
not be ruled out that they had a recurrent or new primary cancer. 
A minority of the participants randomised for surgery + HBO did not comply with the 40 
treatments, mostly because of claustrophobia or malaise. Except for one participant 
who declined due to barotrauma, none of the non-compliant participants were subject to 
any harm caused by HBO treatment.
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The dropout rate was 33%, which was higher than expected. This could be explained by 
the compromised health status of many in this patient group due to a variety of 
comorbidities and sequelae from their previous cancer treatment. 
In the light of the results of the statistical analysis it should be considered which extent 
of a clinical improvement will be sufficient to approve of a treatment modality. While 
planning both trials, we aimed at a 25% improvement to detect a significant difference in 
114 patients. The 25% is, however, an arbitrary level. Although the beneficial effect was 
smaller than anticipated, and not statistically significant in this reduced subset of 
patients, there was an increased chance of healing when HBO was used. This finding, 
although not statistically significant, was observed primarily in grade 3/4 ORN and in 
former or current smokers which seems in line with the theoretical effect of HBO on 
neovascularisation and oxygenation. 
Further investigation should be encouraged because, besides this trial, only one French 
multicentre trial from 2004 by Annane and co-workers has been published [35]. The 
results from this trial showed significantly higher recovery (32%) in the placebo arm than 
in the HBO arm (19%). However, major concerns were raised about the design of the 
trial regarding many factors such as diagnostic criteria, grading/classification of the 
ORN, lack of compliancy with standard HBO guidelines and lack of stratification.  
Overall, there are concerns regarding the validity of the conclusions regarding the effect 
of HBO as a mono-modality treatment of ORN in the Annane trial [36] instead of the 
HBO treatment additional to surgery. 
Evaluation of secondary endpoints also showed a beneficial effect of HBO (as part of 
the combination HBO + surgery) on RT-induced xerostomia, unstimulated salivary flow 
rate, and dysphagia, although not statistically significant in multivariate analysis. Current 
literature reports that HBO has the potential to relieve various symptoms in ORN 
patients, such as hyposalivation and xerostomia (46-49), contributing to an overall 
improvement in quality of life [37]. 
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Within the enrolment time of approximately 10 years, the accuracy of RT has 
continuously improved, leading to a more precise delivery of the RT treatment and 
potentially less toxicity of the surrounding normal structures [5,34,38–43]. Meanwhile, 
the incidence of head and neck cancer is increasing, as well as the five-year survival 
rate [44,45]. The onset of ORN occurs mainly within a couple of years after RT [46], but 
may occur many years later as well [5]. Consequently, treatment of ORN will remain a 
relevant issue despite ongoing improvements in cancer treatment. 
As expected, we observed variable individual responses to the treatment modality HBO 
+ surgery, as some participants did not benefit, whereas others healed successfully. It 
was, however, surprising that smoking status did not independently predict impaired 
healing on multivariate analysis (Supplementary Table 2). This may be explained by the 
small number of enrolled patients and due to the high healing potential in non-smokers 
after surgery irrespectively of HBO (74%) rendering it unlikely that any intervention 
would be able to demonstrate an effect of a considerable value. Due to the physiology 
of the treatment, it was expected that smoking would influence the delivery of oxygen to 
the tissues. As alluded to above, there was a trend of a negative effect primarily in 
grade 3/4 compared to grade 2 and in current/former smokers compared to the lifelong 
non-smokers.
Another explanation for the individual response is the complexity of the surgical 
intervention, which may as well influence the response to treatment. The anatomy of the 
defects varies considerably with regards to size, dimension and proximity to critical 
structures with potential implications for oral function, aesthetics and sensibility. 
Depending on the anatomical defect, primary closure may be difficult to obtain and the 
risk of infection and furtherly compromised healing will be present. This may be 
reinforced by individual comorbidities, increasingly impairing the healing potential. 
Finally, the variability in time span from RT to trial participation may affect the individual 
treatment response, as the RT-induced pathophysiological changes evolve over time. 
Thus, the timing of HBO may affect the individual response. 
Sham treatment was considered in the planning phase of both DAHANCA-21 and 
NWHHT2009-1, but was abandoned mainly because of a potential hindering of 
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recruitment. Another reason was of ethical nature. Having patients travel far and spend 
many hours in a HBO2 chamber while receiving only sham treatment would not be 
approved by the ethical committees. Moreover, creating a realistic scenario for sham 
treatment would require additional financial support, which was unrealistic to obtain. We 
are aware, though, that sham treatment might increase the trial quality. 
Currently, there are no well-documented alternatives to HBO in supporting bone healing 
combined with surgical intervention of ORN. 
To conclude, the attrition rate to HBO after surgery for osteoradionecrosis of the 
mandible, as well as acquisition of patient reported outcomes, was modest in this 
multinational, multicenter clinical trial. Hyperbaric oxygen did not significantly improve 
the healing outcome of osteoradionecrosis after surgical removal of necrotic bone, and 
no recommendations for HBO after surgery for ORN of the mandible may be proposed 
from this study. On the other hand, no recommendation can be done to abandon the 
use of HBO in the treatment of ORN based on this study as well. This would be a type II 
error due to the fact that the trial was underpowered and the results, therefore, are not 
significant. We encourage further research of the effect of HBO as well as relevant 
alternatives to HBO with regards to ORN.
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 Table 1. Primary clinical endpoint. 
Grade Definition       
0 No evidence of ORN, defined as mucosal coverage
 of the mandible and no radiologic evidence of ORN    
1 Small (<2 mm), asymptomatic and radiographically undetectable
 bone exposures with no interference with ADL    
2 Indication for minimal sequestrectomy, having symptoms
 with limited interference with ADL     
3 Indication for larger sequestrectomy, yet above the 
 mandibular canal and functional limitations interfering with ADL  
4 Invalidating ORN, defined as an indication for resection with disruption of
continuity or bone necrosis with extension below the mandibular canal,
 severely interfering with ADL      
Staging of ORN based on CTCAE v 3.0. Grade 0 and 1 were only registered at evaluation of the primary endpoint at 
1-year follow up, as all included patients had verified ORN and indication for treatment at inclusion. 
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Table 2. Patient and treatment characteristics.
 All Surgery Surgery + HBO
 N % N % N %
P value
Number randomised 97 100.0% 51 52.6% 46 47,4%
  DAHANCA-21 77 79,4% 40 41.2% 37 38.2%
  NWHHT 2009-1 20 20,6% 11 11.3% 9 9.3%
Number included in analysis 65 100.0% 35 53.8% 30 46.2%
  DAHANCA-21 54 83.1% 30 46.2% 24 36.9%
  NWHHT 2009-1 11 16.9% 5 7.7% 6 9.2%
Age (years)
Median (range) 61 (49-80) 61 (49-80) 60 (51-78) 0.80
Sex
Female 10 15.4% 5 14.3% 5 16.7% 1.00
Male 55 84.6% 30 85.7% 25 83.3%
Smoking
Never 15 23.1% 7 20.0% 8 26.7% 0.14
Former 30 46.2% 20 57.1% 10 33.3%
Current 20 30.8% 8 22.9% 12 40.0%
Surgery
Minor sequestrectomy 11 16.9% 7 20.0% 4 13.3% 0.83
  Marginal rim resection 33 50.8% 16 45.7% 17 56.7%
Segmental resection of the mandible 19 29.2% 11 31.4% 8 26.7%
None 2 3.1% 1 2.9% 1 3.3%
Baseline activities of daily living (ADL)
Grade 0 3 4.6% 2 5.7% 1 3.3% 0.35
Grade 1 7 10.8% 4 11.4% 3 10.0%
Grade 2 11 16.9% 9 25.7% 2 6.7%
Grade 3 28 43.1% 12 34.3% 16 53.3%
Grade 4 5 7.7% 3 8.6% 2 6.7%
Unknown 11 16.9% 5 14.3% 6 20.0%
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N % N % N %
P value OR(95% CI)
ORN healed
(grade 0-1) 39 60% 18 51% 21 70% 0.13 2.2 (0.7-7.0)
ORN not healed
(grade 2-4) 26 40% 17 49% 9 30%
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Figure legends
Figure 1. Flowchart of patients included in the study.
Figure 2. Predicted chance of being healed 1 year after surgery based on multivariate 
binary logistic regression model including baseline ORN grade and smoking. 
Predictions are calculated as average adjusted predictions and differences are average 
marginal effects (with 95% CI).
Figure 3. Improvement in ADL score from baseline to 1 year after surgery by treatment 









Table 1. Primary clinical endpoint. 
Grade* Definition
0 No evidence of ORN, defined as mucosal coverage of the mandible and no radiologic evidence of ORN
1 Small (<2 mm), asymptomatic and radiographically undetectable bone exposures with no interference with ADL
2 Indication for minimal sequestrectomy, having symptoms with limited interference with ADL
3 Indication for larger sequestrectomy, yet above the mandibular canal and functional limitations interfering with ADL
4 Invalidating ORN, defined as an indication for resection with disruption of continuity or bone necrosis with extension below the mandibular canal, severely interfering with ADL
* Staging of ORN based on CTCAE v 3.0. Grade 0 and 1 were only registered at evaluation of the primary endpoint at 1-year follow up, as all 
included patients had verified ORN and indication for treatment at inclusion. 
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Table 2. Patient and treatment characteristics.
 All Surgery Surgery + HBO
 N % N % N %
P value
Number randomised 97 100.0% 51 52.6% 46 47,4%
DAHANCA-21 77 79,4% 40 41.2% 37 38.2%
NWHHT 2009-1 20 20,6% 11 11.3% 9 9.3%
Number included in analysis 65 100.0% 35 53.8% 30 46.2%
DAHANCA-21 54 83.1% 30 46.2% 24 36.9%
NWHHT 2009-1 11 16.9% 5 7.7% 6 9.2%
Age (years)
Median (range) 61 (49-80) 61 (49-80) 60 (51-78) 0.80
Sex
Female 10 15.4% 5 14.3% 5 16.7% 1.00
Male 55 84.6% 30 85.7% 25 83.3%
Smoking
Never 15 23.1% 7 20.0% 8 26.7% 0.14
Former 30 46.2% 20 57.1% 10 33.3%
Current 20 30.8% 8 22.9% 12 40.0%
Surgery
Minor sequestrectomy 11 16.9% 7 20.0% 4 13.3% 0.83
Marginal rim resection 33 50.8% 16 45.7% 17 56.7%
Segmental resection of the mandible 19 29.2% 11 31.4% 8 26.7%
None 2 3.1% 1 2.9% 1 3.3%
Baseline activities of daily living (ADL)
Grade 0 3 4.6% 2 5.7% 1 3.3% 0.35
Grade 1 7 10.8% 4 11.4% 3 10.0%
Grade 2 11 16.9% 9 25.7% 2 6.7%
Grade 3 28 43.1% 12 34.3% 16 53.3%
Grade 4 5 7.7% 3 8.6% 2 6.7%
Unknown 11 16.9% 5 14.3% 6 20.0%
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N % N % N %
P value OR(95% CI)
ORN healed
(grade 0-1) 39 60% 18 51% 21 70% 0.13 2.2 (0.7-7.0)
ORN not healed
(grade 2-4) 26 40% 17 49% 9 30%
